Prelude Therapeutics Inc 8-K

What Happened Prelude Therapeutics (PRLD) announced on April 15, 2026 that its Board appointed Charles Q. Morris, M.D., age 61, as Chief Medical Officer effective April 20, 2026. The Compensation Committee approved an employment agreement that sets Dr. Morris’s initial base salary at $535,000 and provides an annual discretionary target bonus of up to 40% of base salary.

Key Details

• Appointment announced April 15, 2026; effective Appointment Date: April 20, 2026.
• Initial annual base salary: $535,000; Target Bonus: up to 40% of base salary.
• Equity: option to purchase up to 450,000 shares under the 2020 Equity Incentive Plan; vesting is 25% at one year, then monthly vesting over the next 36 months (1/48th monthly).
• Severance: if terminated without “Cause” or resigns for “Good Reason” (and signs a release), Dr. Morris would receive nine months’ continued base salary and up to nine months of healthcare premium payments; if such termination occurs within 12 months after a Change in Control, he would receive 12 months’ salary, 100% of his annual Target Bonus, up to 12 months of healthcare premiums, and 100% accelerated vesting of then‑outstanding equity awards.
• Company expects to enter its standard indemnification agreement; no related-person transactions or family relationships reported.

Why It Matters This 8‑K reports a senior executive hire with significant clinical leadership experience, which is relevant to Prelude’s drug development and regulatory strategy. The compensation package includes a sizable equity grant (450,000‑share option) that aligns the new CMO’s incentives with long‑term company performance and could affect future dilution depending on exercise. The severance and Change‑in‑Control protections are standard executive safeguards but notable for governance and potential future cash/equity obligations. The full employment agreement will be filed as an exhibit to the company’s next Form 10‑Q.